Shattuck Labs, Inc. (STTK) announced on Monday that the FDA has granted orphan drug designation to their primary clinical candidate SL-172154 for treating Acute Myeloid Leukemia or AML.
The company also expects to share further data from the Phase 1B dose expansion clinical trial of SL-172154 with azacitidine in frontline higher-risk myelodysplastic syndromes and TP53m AML patients at a poster presentation at the European Hematology Association 2024 Congress.
Acute Myeloid Leukemia is a form of cancer affecting the blood and bone marrow characterized by an overabundance of immature white blood cells.
For comments and feedback: editorial@rttnews.com